Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening
- PMID: 29427496
- DOI: 10.1111/liv.13682
Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening
Abstract
CLDs represent an important, and certainly underestimated, global public health problem. CLDs are highly prevalent and silent, related to different, sometimes associated causes. The distribution of the causes of these diseases is slowly changing, and within the next decade, the proportion of virus-induced CLDs will certainly decrease significantly while the proportion of NASH will increase. There is an urgent need for effective global actions including education, prevention and early diagnosis to manage and treat CLDs, thus preventing cirrhosis-related morbidity and mortality. Our role is to increase the awareness of the public, healthcare professionals and public health authorities to encourage active policies for early management that will decrease the short- and long-term public health burden of these diseases. Because necroinflammation is the key mechanism in the progression of CLDs, it should be detected early. Thus, large-scale screening for CLDs is needed. ALT levels are an easy and inexpensive marker of liver necroinflammation and could be the first-line tool in this process.
Keywords: ALT; NAFLD; NASH; alcoholic liver disease; chronic liver disease; cirrhosis; epidemiology; hepatitis B; hepatitis C; hepatocellular carcinoma; screening.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
NIH consensus development statement on management of hepatitis B.NIH Consens State Sci Statements. 2008 Oct 22-24;25(2):1-29. NIH Consens State Sci Statements. 2008. PMID: 18949020
-
The profiling of plasma free amino acids and the relationship between serum albumin and plasma-branched chain amino acids in chronic liver disease: a single-center retrospective study.J Gastroenterol. 2018 Aug;53(8):978-988. doi: 10.1007/s00535-018-1435-5. Epub 2018 Jan 27. J Gastroenterol. 2018. PMID: 29380062
-
Angiogenesis in chronic liver disease and its complications.Liver Int. 2011 Feb;31(2):146-62. doi: 10.1111/j.1478-3231.2010.02369.x. Epub 2010 Nov 15. Liver Int. 2011. PMID: 21073649 Review.
-
Evolution of the determinants of chronic liver disease in Quebec.Chronic Dis Inj Can. 2013 Jun;33(3):137-45. Chronic Dis Inj Can. 2013. PMID: 23735453 English, French.
-
[ALT screening for chronic liver diseases: scrutinizing the evidence].Z Gastroenterol. 2010 Jan;48(1):46-55. doi: 10.1055/s-0028-1109980. Epub 2010 Jan 13. Z Gastroenterol. 2010. PMID: 20072996 Review. German.
Cited by
-
Comparison of the single-cell and single-nucleus hepatic myeloid landscape within decompensated cirrhosis patients.Front Immunol. 2024 Feb 6;15:1346520. doi: 10.3389/fimmu.2024.1346520. eCollection 2024. Front Immunol. 2024. PMID: 38380322 Free PMC article.
-
Emerging Treatment Options for Sarcopenia in Chronic Liver Disease.Life (Basel). 2021 Mar 17;11(3):250. doi: 10.3390/life11030250. Life (Basel). 2021. PMID: 33803020 Free PMC article. Review.
-
Tracking matricellular protein SPARC in extracellular vesicles as a non-destructive method to evaluate lipid-based antifibrotic treatments.Commun Biol. 2022 Oct 30;5(1):1155. doi: 10.1038/s42003-022-04123-z. Commun Biol. 2022. PMID: 36310239 Free PMC article.
-
Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease.Stem Cell Res Ther. 2022 May 3;13(1):179. doi: 10.1186/s13287-022-02858-4. Stem Cell Res Ther. 2022. PMID: 35505419 Free PMC article. Review.
-
A high-throughput technique to map cell images to cell positions using a 3D imaging flow cytometer.Proc Natl Acad Sci U S A. 2022 Feb 22;119(8):e2118068119. doi: 10.1073/pnas.2118068119. Proc Natl Acad Sci U S A. 2022. PMID: 35173045 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
